June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Adalimumab in non-infectious uveitis – efficacy across different etiologies in the VISUAL I and VISUAL II trials
Author Affiliations & Notes
  • Pauline Merrill
    Rush University Medical Center, Oak Park, Illinois, United States
  • Albert T Vitale
    University of Utah, Utah, Utah, United States
  • Manfred Zierhut
    University of Tuebingen, Tuebingen, Germany
  • Eric Fortin
    University of Montreal, Montreal, Quebec, Canada
  • Hiroshi Goto
    Tokyo Medical University, Tokyo, Japan
  • Martina Kron
    AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
  • Samir R Tari
    AbbVie Inc, North Chicago, Illinois, United States
  • Sophia Pathai
    AbbVie Ltd, Maidenhead, United Kingdom
  • Footnotes
    Commercial Relationships   Pauline Merrill, AbbVie (C), Santen (C); Albert Vitale, ACIONT (C); Manfred Zierhut, AbbVie (C), Santen (C); Eric Fortin, AbbVie (C), Alcon (C), Allergan (C); Hiroshi Goto, AbbVie (C); Martina Kron, AbbVie (I); Samir Tari, AbbVie (I); Sophia Pathai, AbbVie (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 518. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pauline Merrill, Albert T Vitale, Manfred Zierhut, Eric Fortin, Hiroshi Goto, Martina Kron, Samir R Tari, Sophia Pathai; Adalimumab in non-infectious uveitis – efficacy across different etiologies in the VISUAL I and VISUAL II trials. Invest. Ophthalmol. Vis. Sci. 2017;58(8):518.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess adalimumab (ADA) efficacy in active and inactive, non-infectious uveitis across different etiologies in patients who were recruited as part of the VISUAL program.

Methods : Exploratory data analyses from two global phase 3, double-masked trials: VISUAL I (patients with active uveitis despite ≥2 weeks of prednisone 10–60 mg/day) and VISUAL II (patients with inactive disease dependent on 10–35 mg/day of prednisone to maintain inactivity) were performed. Patients received placebo (PBO) or ADA subcutaneously (80 mg week 0, followed by 40 mg every other week from week 1 up to 80 weeks). In VISUAL I, all patients received a prednisone burst followed by taper to 0 mg by week 15. In VISUAL II, prednisone taper to 0 mg was mandatory by week 19. The primary endpoint was time to treatment failure (TF) at or after week 6 for VISUAL I; and at or after week 2 for VISUAL II 1, 2. For this analysis, patients were categorized into different uveitis etiologies which they presented at study entry. Hazard ratios (HR) for time to TF were obtained for each uveitis etiology.

Results : The efficacy of ADA was significantly greater than PBO in the largest subgroup of patients with Idiopathic/other uveitis (VISUAL I: 103 and VISUAL II: 90) etiology in both VISUAL I1 and VISUAL II trials. All other subgroups showed a trend in favor of ADA, except for Sarcoidosis subgroup in the VISUAL II trial (Figure). Overall safety for both trials has been previously reported 1,2.

Conclusions : These exploratory analyses from the VISUAL I and VISUAL II trials show significantly higher efficacy in ADA-treated patients over PBO in ‘idiopathic/other’ diagnoses of patients with both active and inactive non-infectious uveitis. Furthermore, across different uveitis etiologies, these analyses suggest that ADA-treated patients had a prolonged time to treatment failure compared to PBO.

References:
1) Jaffe GJ, Dick AD, Brezin AP, et al. N Engl J Med (2016); 375:932-43
2) Nguyen QD, Merrill PT, Jaffe GJ, et al. The Lancet (2016); 388(10050): 1183-92

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Figure: Hazard ratios of time to treatment failure by uveitis etiologies. VISUAL I (A) and VISUAL II* (B) clinical trials.

Figure: Hazard ratios of time to treatment failure by uveitis etiologies. VISUAL I (A) and VISUAL II* (B) clinical trials.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×